23:05 , Aug 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2018. Therapeutic targets are defined as any protein, gene or other molecule...
17:12 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Allakos spikes after pricing upsized IPO above range

Allakos Inc. (NASDAQ:ALLK) gained $13.25 (74%) to $31.25 July 19 after it raised $128.4 million through the sale of 7.1 million shares at $18 in an upsized IPO. Goldman Sachs, Jefferies and William Blair are...
14:27 , Jul 19, 2018 |  BC Extra  |  Financial News

Allakos spikes after pricing upsized IPO above range

Allakos Inc. (NASDAQ:ALLK) gained $13.25 (74%) to $31.25 Thursday after it raised $128.4 million through the sale of 7.1 million shares at $18 in an upsized IPO. Goldman Sachs, Jefferies and William Blair are underwriters. The...
21:39 , Jun 23, 2018 |  BC Extra  |  Financial News

Latest batch of IPO filings: Rubius, Constellation, Replimune, Allakos

As a busy week for IPO pricings came to a close, several more companies filed for NASDAQ listings late Friday, further stocking an IPO pipeline of companies likely to seek liquidity during a tight calendar...
14:48 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Allakos reports Phase I data for AK002 in healthy volunteers

Allakos Inc. (San Carlos, Calif.) reported data from a Phase I trial in healthy volunteers showing that single doses of 0.001-1 mg/kg IV AK002 were generally well tolerated. The company is developing the non-fucosylated IgG1...
16:27 , Dec 15, 2017 |  BC Week In Review  |  Financial News

Allakos raises $100M in series B

Allakos Inc. (San Carlos, Calif.) raised $100 million in a series B round led by New Enterprise Associates. Redmile Group, Partner Fund Management, Rock Springs Capital, LifeSci Venture Partners, Samsara BioCapital and an undisclosed institutional...
00:47 , Dec 14, 2017 |  BC Extra  |  Financial News

NEA leads $100M Allakos series B

Allakos Inc. (San Carlos, Calif.) raised $100 million in a series B round led by New Enterprise Associates. Redmile Group, Partner Fund Management, Rock Springs Capital, LifeSci Venture Partners, Samsara BioCapital and an undisclosed institutional...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

AK002: Phase I started

Allakos began an open-label, German Phase I trial to evaluate single ascending doses of IV AK002 in about 30 patients. Allakos Inc., San Carlos, Calif.   Product: AK002   Business: Hematology   Molecular target: Undisclosed   Description: Undisclosed...